Molecular Allergen Immunotherapy (Molecular AIT) is Worg's globally exclusive AIT drug development platform. By identifying the major sensitizing proteins in allergens and achieving high molecular purity, it offers a safer, more effective, and convenient AIT treatment option for allergic disease patients.
Compared to traditional natural extract AIT drugs, molecular AIT products have clear, high-content active ingredients, low side effects, high treatment efficacy, and ease of use.
Worg has already launched 3 molecular AIT products overseas and is actively advancing clinical trials and registration preparations for these products in China.
House dust mites (HDM), including Dermatophagoides pteronyssinus and Dermatophagoides farinae), remains one of the most dominant allergen worldwide, with prevalence continuing to climb and reinforcing its leading position. the HDM sensitization rate in China exceeds 50%, while the US and EU are approximately 30% respectively, it is estimated that more than 100 million people globally allergic to HDM.
MOL Mite is the only dust mite AIT product globally that targets three major sensitizing proteins, covering over 90% of allergies caused by dust mites.
Plants of the genus Cupressus are widely distributed in regions such as Europe, North America, and northern China. Taking Spain as an example, the sensitization rate to cypress pollen in this country reaches 6%. Japanese cedar is also one of the most significant allergens in Japan.
Worg's cypress molecular AIT product contains purified major allergens derived from cypress pollen, covering over 94% of patients allergic to cypress
The sensitization rate for fungal allergens in patients with respiratory allergic diseases worldwide reaches 3.3%. In particular, the sensitization rates to Alternaria alternata in China and the United States reach up to 6% and 13% respectively. In China, the fungus sensitization rate in children is significantly higher than that in adults, and the rate continues to rise among children suffering from rhinitis and asthma.
Worg's fungal molecular AIT product contains purified major allergens derived from Alternaria species, covering over 90% of patients allergic to fungi.
Scan
WeChat official account
A wholly-owned subsidiary of Worg PHARMA
